The effect of cystic fibrosis on many organs and the frequent lung infections means that it is mostly diagnosed in childhood. Somehow, for Verônica Stasiak Bednarczuk, that diagnosis did not arrive ...

Its architect's daughter has cystic fibrosis—and benefits from a "miracle drug" backed by an agency he's attacking.

For Vertex these days, it’s all about the launches of three new products—sickle cell disease gene therapy Casgevy, the ...

Vertex reports mixed fourth-quarter 2024 results as earnings miss estimates while revenues beat the same. Trikafta/Kaftrio ...

Stuart Arbuckle, who’s been with Vertex since 2012, plans to retire from his role in July. His departure comes as Vertex ...

Despite "another impressive quarterly revenue beat" on Tuesday and solid guidance, Vertex stock dipped on light profit.

Vertex reported solid fourth-quarter numbers throughout its business. While the company's earnings per share came in slightly ...

Good day and welcome to the Vertex Pharmaceuticals fourth quarter of 2024 earnings call. (Operator Instructions) Please note this event is being recorded. I would now like to turn the conference over ...

BMO Capital Markets maintained its Outperform rating and $545.00 price target on Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX), representing a 16% upside from the current price of $469.97. With a ...

Scotiabank (TSX:BNS) analyst Greg Harrison updated the price target for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX), a $121 billion market cap biotechnology company, to $450, up from the ...

Vertex Pharmaceuticals is working toward making its recently approved non-opioid pain medicine Journavx not only broadly ...

The cystic fibrosis treatment leader exceeded revenue expectations, but missed slightly on earnings per share.